Medtech and pharma and businesses can take steps to avoid having to claim on their cyber insurance policies, says Edward Machin of law firm Ropes & Gray.
Six years ago I was on secondment to a multinational pharma firm to kickstart its preparation for General Data Protection Regulation (GDPR) compliance.
Things were going smoothly until the firm became a victim of the infamous NotPetya malware. Numerous organizations were severely affected...
Create an account to read this article
Already a subscriber?
During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.
Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.
Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.
An interactive look at pharma, medtech and diagnostics deals made during July 2025. Data courtesy of Biomedtracker.
